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ABSTRACT
Aim In the Eplerenone in Mild Patients Hospitalization
and Survival Study in Heart Failure (EMPHASIS-HF),
aldosterone blockade with eplerenone decreased
mortality and hospitalisation in patients with mild
symptoms (New York Heart Association class II) and
chronic systolic heart failure (HF). The present study
evaluated the cost-effectiveness of eplerenone in the
treatment of these patients in the UK and Spain.
Methods and results Results from the EMPHASIS-HF
trial were used to develop a discrete-event simulation
model estimating lifetime direct costs and effects (life
years and quality-adjusted life years (QALYs) gained) of
the addition of eplerenone to standard care among
patients with chronic systolic HF and mild symptoms.
Eplerenone plus standard care compared with standard
care alone increased lifetime direct costs per patient by
£4284 for the UK and €7358 for Spain, with additional
quality-adjusted life expectancy of 1.22 QALYs for the
UK and 1.33 QALYs for Spain. Mean lifetime costs were
£3520 per QALY in the UK and €5532 per QALY in
Spain. Probabilistic sensitivity analysis suggested a 100%
likelihood of eplerenone being regarded as cost-effective
at a willingness-to-pay threshold of £20 000 per QALY
(UK) or €30 000 per QALY (Spain).
Conclusions By currently accepted standards of value
for money, the addition of eplerenone to optimal
medical therapy for patients with chronic systolic HF and
mild symptoms is likely to be cost-effective.
INTRODUCTION
Around 1%–2% of adults in Europe have heart
failure (HF) which causes an immense symptom
burden due to breathlessness, fatigue and oedema,
greatly reduces quality of life and is a leading cause
of hospital admission and, therefore, healthcare
expenditure.1 2 Mortality within 12 months of a
HF hospital admission is 30%–40%, rising to a
5-year mortality rate of 50%–75%.3 4
The primary goals of the treatment of HF are,
therefore, to relieve symptoms, reduce the rate of
hospitalisation and improve survival.5 ACE inhibi-
tors and β-blockers have been shown to achieve
these goals in patients with HF and reduced EF
(HF-REF), irrespective of symptom severity
(New York Heart Association (NYHA) class II–IV),
and are thus strongly recommended (class I, evi-
dence level A) in clinical guidelines on the basis of
multiple clinical trials.5
Until recently, mineralocorticoid receptor antago-
nists (MRAs) were recommended (class I, evidence
level B) only in patients with moderate-to-severe
symptoms (NYHA class III or IV) on the basis of
the Randomized Aldactone Evaluation Study
(RALES).6 This recommendation has now been
strengthened (class I, evidence level A) and broa-
dened (to include all patients with symptomatic
HF-REF) following the Eplerenone in Mild patients
Hospitalization and Survival Study in Heart Failure
(EMPHASIS-HF), which showed a reduction in
mortality and all-cause hospitalisation when an
MRA was added to optimal evidence-based therapy
in patients with mild symptoms (NYHA class II
HF), LVEF ≤30% (or, if >30%–35%, a QRS dur-
ation of >130 ms on electrocardiography) and
recent hospitalisation for a cardiovascular (CV)
reason, elevated plasma B-type natriuretic peptide
(BNP) or N-terminal pro-BNP.7 These ﬁndings are
supported by a further trial, the Eplerenone
Post-Acute Myocardial Infarction Heart Failure
Efﬁcacy and Survival Study (EPHESUS), in patients
with myocardial infarction complicated by left ven-
tricular systolic dysfunction and HF.8
We have evaluated the cost-effectiveness of epler-
enone in patients with HF-REF and mild symptoms
(NYHA class II) because, beside efﬁcacy and safety,
the adoption of new treatments is also inﬂuenced
by whether the added value is worth the added
cost. We have done this from the perspective of
two European countries, the UK and Spain.
METHODS
Model description
A discrete-event simulation model was developed
to project the rates and times of important clinical
events and assign to these lifetime costs and
quality-of-life consequences (ﬁgure 1). Two treat-
ment pathways were simulated, in line with the
trial protocol: standard therapy with the addition
of eplerenone (starting dose of 25 mg once daily; at
4 weeks, increased to 50 mg once daily) and stand-
ard therapy with no additional active treatment
(standard care). Model outputs are presented in
terms of mean life expectancy, quality-adjusted life
expectancy, direct costs and incremental cost-
effectiveness ratios (ICERs).
The simulated patient population in the model
was derived from that enrolled in EMPHASIS-HF.7
All patients were in NYHA class II, with a mean
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age of 69, had a mean LVEF of 26% and 78% of patients were
men. Only concomitant medication usage at enrolment was
reported in the trial and so it was assumed subjects remained on
the same medication for their lifetimes.
A discrete-event simulation models time to clinically and eco-
nomically meaningful events on the basis of individually-
simulated patients. This method was chosen in preference to a
Markov model as it is possible to model an unlimited number
of events for each patient and make the probability of events
contingent on time, the number and type of events the patient
has already experienced, and the patient’s characteristics (such
as age).9
Patient-level data from EMPHASIS-HF were used to deter-
mine risk equations for each event by ﬁtting a distribution to
the time to each event. Treatment effectiveness was captured in
the model by tracking progress to the following health states
reported in the trial: HF hospitalisation, other CV hospitalisa-
tion, new-onset atrial ﬁbrillation, implantation of cardiac
resynchronisation therapy (CRT) or implantable cardioverter-
deﬁbrillator (ICD) devices, adverse events, discontinuation of
eplerenone, CV mortality, and non-CV mortality.
The adverse events included within the model are the key
events reported in EMPHASIS-HF: hyperkalaemia, hypokal-
aemia, renal failure, hypotension and gynaecomastia.7
New-onset diabetes, heart transplants, dialysis and kidney trans-
plants were not included in the model because the rates were
low and either similar or the same for both trial arms, meaning
that inclusion would not change the model results.10 In add-
ition, consideration was given to modelling the change in
NYHA class as time progressed, but as there was no signiﬁcant
change in NYHA class between the two arms (p=0.14), the
majority of patients remained in class II (≥75% of patients at all
time points up to month 42 were in NYHA class on both arms)
and available evidence to extrapolate beyond the trial is limited,
this was not included. This implies that the reported beneﬁts of
eplerenone are instead based upon the reduction in mortality,
hospitalisations and new-onset atrial ﬁbrillation.
Figure 1 provides an overview of the model ﬂow. In brief,
simulated patients were created and individual times to events
were randomly assigned to them based upon the risk equations
for each model event (see online supplementary appendix),
derived from EMPHASIS-HF data for each arm separately,
except non-CV mortality which was assumed to be the same for
eplerenone and standard care. Each patient was then copied and
the two identical patients were assigned to treatment with either
standard care or eplerenone plus standard care.
The model simulated 25 000 patients for each treatment in
order to minimise stochastic error and provide an appropriate
level of certainty in the ICER (SD in the ICER over repeated
simulations <£100 (€120)).
At the start of the model, patient’s times to event were simu-
lated and the patient progressed to the ﬁrst event to occur.
Following the event there were two possible options:
1. The patient exited the model if:
A. death occurred
B. an ICD or CRT device was implanted: remaining life
years, costs and quality-adjusted life years (QALYs) were
assigned to patients at this point based upon an assess-
ment conducted for the National Institute of Health and
Care Excellence on the effectiveness of these devices;11
the EMPHASIS trial information was not sufﬁcient to
estimate device effect due to lack of sufﬁcient follow-up
post device implantation.
2. The patient remained in the model and the time to the next
event was calculated.
If the event was deemed to inﬂuence the time of other events,
the times to these events were recalculated. Events that were
deemed to interact in this way were: HF (and other CV) hospi-
talisations, which increase the likelihood of both CV mortality
and repeat hospitalisations, and adverse events, which increase
the likelihood of future adverse events.
Parametric survival models (Weibull, exponential and log-
normal) were tested and the best ﬁtting models used to describe
time-to-event. Similar parametric models were ﬁtted where
necessary to outcomes with multiple events following the
method recommended by Harrell.12
Patients were followed over the course of the simulation with
their characteristics updated over time. It was assumed that
patients who discontinued treatment (after a hospitalisation or
adverse event) with eplerenone returned to standard care.
Patient discontinuation rates were based on the EMPHASIS-HF
data.
Figure 1 Model structure. CV,
cardiovascular; HF, heart failure; QALY,
quality-adjusted life year.
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It should be noted that the clinical data used in the model
included recurrent events and not just the ﬁrst events reported
in the main results paper from EMPHASIS-HF.7 13
A scenario is included where patients only exit the model on
death, and devices are not included within the model, to test
the sensitivity of the results.
In the base-case analysis, a lifetime horizon was chosen to
fully capture the costs and quality-of-life beneﬁts resulting from
treatment with eplerenone given the increased survival. There
were no modelled differences between the two countries in the
standard-treatment practices or the comparators. The model
implementation used Simul8 15.0 and Microsoft Excel 2010.
All cost, quality-of-life and length-of-life outcomes were dis-
counted at 3.5% annually within the UK model and 3.0% annu-
ally within the Spanish model, in line with their national
reimbursement reference cases.
Costs and perspective
Cost inputs for the model are given in table 1. Only initial acute
event costs were accounted for when hospitalisations occurred.
No data were available to estimate the direct costs of death, and
these were not included in the model. This is a conservative
assumption.
The costs for other CV hospitalisations, adverse events and
devices were based on the proportion of patients from the
EMPHASIS-HF trial experiencing each subcategory of event.
The cost of each adverse event is higher on the standard care
arm compared with the eplerenone arm; the types of events
experienced are different and a higher proportion of patients
experiencing adverse events required hospitalisation (23% of
adverse events experienced by patients on the standard care arm
required hospitalisation compared with 15% on the eplerenone
arm). When a patient was ﬁtted with a device, costs were
applied for ﬁtting of the device and each pulse generator
replacement that would be required for the patient’s remaining
life span.
Data on prescribed medication were taken from the trial pub-
lication and a weighted average of concomitant medications
(excluding eplerenone) calculated to account for medication
resource usage. Eplerenone was assumed to be prescribed for a
patient’s lifetime or until discontinuation.
The cost of two hospital visits and sets of blood chemistry
tests is included on initiation of treatment with eplerenone.
Thereafter, annual disease management and monitoring costs
are assumed to be the same for standard care and treatment
with eplerenone.
Quality of life
Quality of life was calculated using the utility formula from
Göhler et al14 using the baseline characteristics of the patients
in the EMPHASIS-HF trial. Utility decrements were assigned to
patients as they experienced events. The utility values used
within the model are summarised in table 1.
Sensitivity analysis
A range of deterministic sensitivity analyses were carried out to
test the robustness of the model projections by varying key inputs
and assumptions. One-way parameter sensitivity analyses were
performed by varying each parameter within its likely range
Table 1 Utilities and medication and event costs used within the model
Parameter Input value—UK model Input value—Spanish model Reference
Per annum treatment costs
Eplerenone drug costs £557 €1086 23 24
Standard care drug costs £0 €0 Assumed
Concomitant medications £229 €290 23 24
Eplerenone treatment initiation (one-off )* £463 €119 25–27
Disease management and monitoring £443 €60 25–27
Event-based costs
HF hospitalisation £3463 €3321 25 27
Other CV hospitalisation £3001 €4980 25 27
Adverse event—eplerenone† £237 €786 25 27
Adverse event—standard care† £280 €1133 25 27
Cost of CRT and ICD devices £5842 €9005 25 27
Average CRT and ICD device life 5.8 years 5.8 years 11
Quality-of-life utilities
Baseline utility 0.84 0.84 14
Utility decrement for patients who experience one hospitalisation −0.024 −0.024 14
Utility decrement for patients who experience two hospitalisations −0.031 −0.031 14
Utility decrement for patients who experience three hospitalisations −0.055 −0.055 14
Utility decrement for new-onset atrial fibrillation −0.084 −0.084 28
Lifetime utility decrement for adverse events—eplerenone −0.0003 −0.0003 19
Lifetime utility decrement for adverse events—standard care −0.0001 −0.0001 19
Short-term utility decrement for adverse events—eplerenone‡ −0.0012 −0.0012 19 29
Short-term utility decrement for adverse events—standard care‡ −0.0008 −0.0008 19
*Two hospital appointments with a consultant and two sets of blood chemistry tests.
†The unit costs of the adverse events for each of the five events modelled for the two arms were assumed to be the same. The proportion of patients experiencing each type of event
(hospitalised and non-hospitalised) was calculated using the trial results. Costs are higher on the placebo arm as more patients were hospitalised (23% of adverse events vs 15%) and
more patients experienced renal failure which is the most costly of the five key adverse events included.
‡Applied for 21 days based upon clinician advice.
CRT, cardiac resynchronisation therapy; CV, cardiovascular; HF, heart failure; ICD, implantable cardioverter-defibrillator.
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using the 95% CIs of the parameter distributions (ﬁgure 2). In
addition, a range of scenario analyses were conducted.
A probabilistic sensitivity analysis (PSA) was also performed,
producing 100 pairs of incremental effectiveness and cost
results. These were plotted on a cost-effectiveness plane to illus-
trate the probability of being cost-effective for both countries’
willingness-to-pay (WTP) thresholds (ﬁgure 3).
RESULTS
The results of the base-case analysis projected lifetime improve-
ments in clinical outcomes with increased costs for subjects
receiving eplerenone in addition to standard care compared
with standard care alone and are shown in table 2.
Over a patient’s lifetime, there were higher costs associated
with eplerenone than standard care. The increases in costs pro-
duced by the model were £4284 for the UK and €7358 for
Spain. The main differences in costs between the two countries
were due to the cost of eplerenone (which is higher in Spain
than the UK) and the costs of disease management and monitor-
ing (which are higher in the UK).
Over a patient’s lifetime, the mean quality-adjusted life
expectancy for eplerenone using a discount rate of 3.5% (UK
simulation) was 6.19 versus 4.98 QALYs for standard care (a dif-
ference of 1.22 QALYs). There was a larger improvement in
absolute discounted life expectancy: 7.74 versus 6.23 years for
eplerenone and standard care, respectively.
Using a discount rate of 3% (Spanish simulation), the mean
quality-adjusted life expectancy was 6.53 versus 5.20 QALYs for
eplerenone and standard care, respectively (a difference of 1.33
QALYs). There was a larger improvement in absolute discounted
life expectancy: 8.18 versus 6.52 years for eplerenone and
standard care, respectively. These outcomes produced ICERs of
£3520 per QALY for the UK and €5532 for Spain.
The results of the deterministic sensitivity analyses are pre-
sented in ﬁgure 2. In all cases, the ICER remains below £5500
per QALY in the UK model and below €8500 per QALY in the
Spanish model, indicating that the model is very stable in its pre-
dictions and not sensitive to any one parameter. These ICERs
are well below the accepted WTP thresholds in both of these
countries (£20–30 000per QALY in the UK and €30 000 per
QALY in Spain).
Results from scenario analyses are presented in table 3 and
show that the ICER remains approximately equal to the
accepted WTP thresholds in both countries even when
the EMPHASIS-HF data are used with no extrapolation at
all. The model results are not sensitive to either the utility
decrements applied for events or the rates of device implant-
ation. The ICER improves as the modelled time horizon
increases because longer time horizons allow for more time for
the modelled beneﬁts of eplerenone to be realised.
The mean results of the PSA are very similar to the determin-
istic base case described above. When incorporating the uncer-
tainty around all model inputs, the 100 simulations gave an
overall mean ICER of £6939 (95% Bayesian credibility interval
(£6656; £7222)) for the UK model and €7217 (95% Bayesian
credibility interval (€6905; €7528)) for the Spanish model.
Scatter plots of the 100 pairs of incremental quality-adjusted
life expectancies and lifetime costs are presented in ﬁgure 3. In
all cases, eplerenone provides a QALY beneﬁt over standard care
and the values simulated fall below the £20 000 WTP threshold
within the UK model and below the €30 000 threshold within
the Spanish model, showing that eplerenone is consistently
cost-effective.
DISCUSSION
Based upon the EMPHASIS-HF trial, this modelling analysis
shows that the use of eplerenone in patients with HF-REF and
mild symptoms reduced hospitalisations (particularly HF hospi-
talisations) and the costs associated with these. These savings
partially offset the additional cost of eplerenone treatment (and
Figure 2 Deterministic sensitivity analysis tornado plots. CV, cardiovascular; HF, heart failure; QALY, quality-adjusted life year.
Figure 3 Incremental quality-adjusted life expectancy and lifetime costs. QALY, quality-adjusted life year; WTP, willingness-to-pay threshold.
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extension of life) resulting in very modest ICERs of £3520 and
€5532 per QALY gained for eplerenone versus standard care in
the UK and Spain, respectively. These ICERs are much lower
than the £20 000 WTP threshold in the UK and the €30 000
threshold in Spain, indicating that eplerenone, as an add-on
therapy in the treatment of HF-REF with mild symptoms
(NYHA class II), represents a cost-effective option, generating
additional clinical beneﬁt at an acceptable incremental cost in
both countries. The results were robust to deterministic and
probabilistic sensitivity analyses.
Our ﬁndings are in keeping with the favourable cost-
effectiveness of other disease-modifying therapies in HF-REF,
including ACE inhibitors, angiotensin receptor blockers and
β-blockers.15–18 The common theme, from an economic per-
spective, is the ability of all of these agents to reduce the rate of
hospitalisation for worsening HF, which is the major driver of
the cost of this condition to health services and payers. Indeed,
the reduction is so substantial that the cost savings either largely
balance or even eliminate the additional costs of treatment
(drug and monitoring) and increased longevity (ie, surviving
patients require treatment, including procedures, and remain at
risk of hospitalisation). Although we did not analyse the cost-
effectiveness of eplerenone in other European countries, previ-
ous studies with other effective treatments in HF have shown
consistent ﬁndings in a variety of countries including Germany
and France and there is no reason to believe that eplerenone
would be different.17
When considering the results from a computer simulation
model, it is ideal to be able to validate the clinical outcomes
against empirical data. Unsurprisingly, the model accurately pro-
jects the within-trial outcomes (see online supplementary appen-
dix). For the time beyond the trial follow-up period, the model
also provides a reasonable approximation of current survival
estimates for chronic systolic HF patients, with a mean survival
of approximately 8 years in the standard care arm.3 Within-trial
analysis, for which we have complete certainty in outcomes,
estimated ICERs below the WTP thresholds for both the UK
and Spain.
The much less expensive MRA spironolactone is approved for
the treatment of patients with chronic systolic HF and moderate
to severe symptoms (NYHA class III and IV), based upon the
results of the RALES trial.6 It is not known whether the
spironolactone would have had the same clinical effects
Table 3 Scenario analysis results from the discrete-event
simulation model
Scenario Country
Incremental
costs
Incremental
QALYs ICER
Using EMPHASIS-HF
data with no
extrapolation
UK £940 0.05 £20 730
Spain €1427 0.05 €31 138
Time horizon
2 years
UK £717 0.04 £20 101
Spain €1157 0.04 €32 208
Time horizon
5 years
UK £1160 0.19 £6016
Spain €2340 0.20 €11 932
No utility decrement
for adverse events,
atrial fibrillation or
hospitalisations
UK £4284 1.20 £3558
Spain €7358 1.32 €5584
Increased use of
devices
UK £4495 1.22 £3693
Spain €7396 1.33 €5560
No use of devices UK £3440 1.23 £2802
Spain €5223 1.34 €3893
EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart
Failure; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
Table 2 Base-case scenario results from the discrete-event simulation model
UK Spain
Eplerenone Standard care Difference Eplerenone Standard care Difference
Other CV hospitalisations 1.27 1.23 0.04 As UK
HF hospitalisations 1.32 1.60 −0.28
Diagnosis of atrial fibrillation 0.09 0.12 −0.03
CV mortality 0.71 0.77 −0.05
Non-CV mortality 0.08 0.06 0.02
Adverse events 0.67 0.43 0.24
ICD or CRT 0.59 0.46 0.13
Discontinuation of eplerenone 0.42 – 0.42
Cost of CV hospitalisations £3236 £3240 −£4 €5493 €5478 €15
Cost of HF hospitalisations £3888 £4862 −£973 €3815 €4748 −€932
Cost of active treatment £3873 £0 £3873 €7080 €0 €7080
Cost of concomitant treatment £1773* £1426 £347 €2371 €1889 €481
Cost of devices £3597* £3046 £551 €3641 €3048 €592
Cost of disease management and monitoring £3433* £2761 £672 €488 €389 €99
Cost of adverse events £137 £108 £30 €465 €443 €22
Total cost £18 559 £14 275 £4284 €23 353 €15 995 €7358
Total QALYs 6.19 4.98 1.22 6.53 5.20 1.33
Total life years 7.74 6.23 1.52 8.18 6.52 1.66
ICER £3520 €5532
Cost per life year gained £2825 €4431
*While the rate of use of devices, management and monitoring, and concomitant treatment requirements is either the same for the two arms or lower on the eplerenone arm, as
patients are expected to live longer, the total cost over a patient’s lifetime is higher.
CRT, cardiac resynchronisation therapy; CV, cardiovascular; HF, heart failure; ICD, implantable cardioverter-defibrillator; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted
life year.
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(and therefore economic consequences) as eplerenone in
EMPHASIS-HF. Eplerenone is a selective MRAwhereas spirono-
lactone is non-selective and the two agents have different toler-
ability proﬁles.19 Poorer tolerability and persistence of
spironolactone could result in additional costs that may affect
the difference in drug costs.19
LIMITATIONS
Although the model has been shown to produce clinically realis-
tic projections, there are a number of limitations with this work
that should be noted. First, this is a modelling study and does
not represent empirically collected resource and quality-of-life
outcomes associated with clinical ﬁndings. However, in the
absence of more detailed data from the trial, a computer simula-
tion such as this represents the next best solution. Second, as
the EMPHASIS-HF trial was stopped early, due to early beneﬁt
in the eplerenone-treated group compared with the standard
care arm, there is some uncertainty regarding the long-term out-
comes of eplerenone in the available clinical data. Truncation
issues are particularly likely to impact the absolute cost estimates
for symptomatic decline (eg, device use) as outcomes are mod-
elled based on projections from limited data. Truncated trials
often associated with greater effect sizes, with moderate over-
estimation in trials such as EMPHASIS-HF where more than
500 events were observed.20 Uncertainty around the data has,
however, been included within the modelling approach used
and examined within both probabilistic and deterministic sensi-
tivity analyses. The extent to which EMPHASIS-HF can be gen-
eralised is also limited by design features and other
characteristics of the patients enrolled, including the tendency
for trial patients to be younger and have less comorbidity than
‘real-world’ patients. The model did not take account of indirect
costs, such as loss of earnings and pension payments to survi-
vors, or other costs such as those related to admission to
nursing homes.21 22
CONCLUSIONS
The addition of eplerenone to standard therapy (with an ACE
inhibitor and β-blocker) reduces the risk of all-cause mortality
and all-cause hospitalisation in patients with chronic systolic HF
and mild symptoms (NYHA class II). These clinical beneﬁts
offset a substantial portion of the additional drug cost associated
with eplerenone, yielding favourable cost-effectiveness ratios
well below standard WTP thresholds in the two European coun-
tries studied. Overall, this economic evaluation supports the use
of eplerenone as a cost-effective treatment in eligible patients
with chronic systolic HF and mild symptoms.
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